{
    "medicine_id": "72e5a8d9849e9dfedb17d92a7ca1db312ab2f35e",
    "platform_id": "DB11054",
    "metadata": {
        "name": "HemaCord 500000000 1 25mL Injection",
        "composition": "500000000 1 25mL Human cord blood hematopoietic progenitor cell",
        "clinical_particulars": {
            "therapeutic_indications": "Indicated for use in unrelated donor hematopoietic progenitor cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited acquired or result from myeloablative treatment FDA Label",
            "contraindications": {
                "disease": "There has been no cases of overdose with human cord blood hematopoietic progenitor cell therapy and single doses up to 57 6 x 107 TNC kg have been administered Higher doses of dimethyl sulfoxide DMSO in the infusion mixture may induce altered mental status and coma For DMSO overdosage general supportive care is recommended FDA Label",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Human cord blood hematopoietic progenitor cells constitute the hematopoietic progenitor cells monocytes lymphocytes and granulocytes that are isolated from red blood cells and plasma volume that are collected from the human umbilical cord and placenta FDA Label According to the findings of retrospective data reviews and a single arm prospective study patients with hematologic malignancy who are receiving human cord blood hematopoietic progenitor cell transplantation achieved recovery of neutrophil counts platelet counts erythrocyte counts at rates of 76 83 57 77 and 46 77 respectively FDA Label",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}